Karen Fransis

<i>TP53</i> Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer

Bram De Laere, Steffi Oeyen, Markus Mayrhofer et al. · Clinical Cancer Research · 2018 · 161 citations · Full text

Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis

Markus Mayrhofer, Bram De Laere, Tom Whitington et al. · Genome Medicine · 2018 · 128 citations · Full text

Retzius‐sparing robot‐assisted radical prostatectomy: early learning curve experience in three continents

Antonio Galfano, Silvia Secco, Paolo Dell’Oglio et al. · British Journal of Urology · 2020 · 37 citations · Full text

Multicentre, prospective study on local treatment of metastatic prostate cancer (LoMP study)

Sarah Buelens, Filip Poelaert, Tom Claeys et al. · British Journal of Urology · 2021 · 28 citations · Full text

Circulating tumor cells and survival in abiraterone‐ and enzalutamide‐treated patients with castration‐resistant prostate cancer

Bram De Laere, Steffi Oeyen, Peter Van Oyen et al. · The Prostate · 2018 · 27 citations · Full text